Categories Uncategorized

RYAH Group Inc. (CSE: RYAH) Reports on the Medical Benefits of the “Munchies”

  • Reported on the therapeutic benefit of munchies for nausea and vomiting
  • Recorded over 14,500 sessions from patients seeking relief from nausea
  • Munchies are a medical benefit for those going through chemotherapy or diagnosed with cachexia, also known as a wasting disorder

RYAH Group (CSE: RYAH), the leading data technology company in plant-based medicine, collects data through its IoT dose-measuring devices and AI analytics. Recently the company reported on The Therapeutic Benefit of the Munchies for Nausea and Vomiting. The full article can be found at https://ibn.fm/mgkad.

RYAH is uniquely positioned to collect essential data that can lead to more personalized and targeted care within the health industry. The Company partners with doctors, researchers, product suppliers, and retailers to place its top-rated apps, dose-controlled devices and services into the hands of patients and consumers. *The AI platform aggregates and correlates HIPAA-compliant dosing data from seed to consumption, allowing the company to run in-depth analytical reports. These reports help identify trends and consumer outcomes.

Cannabis has always carried a reputation for causing a case of the “munchies.” While some might find this side effect bothersome, others turn to it for that exact reason. Since 2018, RYAH has recorded over 14,500 sessions with patients seeking relief from nausea with medical cannabis.

Currently, cannabis is a patient-driven choice in treating nausea, vomiting, and appetite loss. Of all the conditions that patients turn to medical cannabis for, nausea and vomiting continue to be two of the most socially and legally accepted. It is common for those going through chemotherapy to seek relief and also used by those who have cachexia, a wasting disorder that causes extreme weight loss, nausea and vomiting. As evidence builds through various clinical studies, cannabinoid therapy may soon become a common doctor-recommended prescription rather than merely a patient’s request.

RYAH first developed and commercialized its smart inhaler in 2018. Since then, it has developed a complete IoT device and data analytics platform with multiple delivery mechanisms that include the Smart-Inhaler, Smart Transdermal Patch, and the Smart Pen.

The company has also developed data-driven platforms for doctors and for patients. RYAH MD is a remote and interactive patient-doctor collaboration and dosing administration platform that allows for real-time monitoring, appointment booking, doctor-patient video calls, science-based strain recommendations and more. For the patient and end-user, there is the PotBotApp. This medical cannabis education mobile app creates a personalized and data-driven resource of potential product matches for the user’s ailments and efficacy goals.

RYAH is rapidly expanding and actively looking for partnerships as it takes its data-driven technology and plant-based medicine global.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035

The global market for brain tumor treatments is experiencing significant transformation powered by advances in…

2 days ago

New Blood Test Shows Potential in Revolutionizing Early Parkinson’s Detection

A team of researchers has developed a “cost-effective” and simple blood test with the potential…

4 days ago

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…

5 days ago

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…

6 days ago

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…

1 week ago

Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…

1 week ago